Form 4: Inmune Bio Director Acquires 32,500 Stock Options

Marcia Allen, a director at Inmune Bio, Inc., was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Summary

• Marcia Allen, a director of Inmune Bio, Inc., has reported a transaction involving the acquisition of stock options.
• On December 5, 2024, Ms. Allen was granted 32,500 stock options at an exercise price of $5.05 per share.
• These options are granted under the 2021 Stock Incentive Plan.
• The options will fully vest and become exercisable on December 5, 2026, two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications or unusual circumstances.

Positives

• The grant of stock options to a director aligns their interests with the company's long-term performance.
• The vesting period of two years encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the company's success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting period of two years is typical for such grants, designed to encourage long-term commitment and performance.
• The exercise price of $5.05 is a standard feature of stock options, allowing the holder to purchase shares at a predetermined price.

Stakeholder Impact

• The stock option grant may have a positive impact on shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Inmune Bio, equity, director, vesting